CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by HM Payson & Co.

HM Payson & Co. raised its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 115.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,330 shares of the company’s stock after purchasing an additional 1,250 shares during the period. HM Payson & Co.’s holdings in CRISPR Therapeutics were worth $109,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of CRSP. Pinnacle Associates Ltd. bought a new stake in shares of CRISPR Therapeutics during the third quarter valued at approximately $188,000. China Universal Asset Management Co. Ltd. increased its position in CRISPR Therapeutics by 64.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,381 shares of the company’s stock valued at $770,000 after acquiring an additional 6,405 shares during the period. SFE Investment Counsel raised its stake in CRISPR Therapeutics by 8.0% during the 3rd quarter. SFE Investment Counsel now owns 6,312 shares of the company’s stock valued at $297,000 after acquiring an additional 466 shares in the last quarter. Patriot Financial Group Insurance Agency LLC boosted its position in CRISPR Therapeutics by 7.9% during the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 29,586 shares of the company’s stock worth $1,390,000 after acquiring an additional 2,165 shares during the period. Finally, Farrow Financial Inc. grew its stake in shares of CRISPR Therapeutics by 14.2% in the third quarter. Farrow Financial Inc. now owns 19,827 shares of the company’s stock worth $931,000 after purchasing an additional 2,467 shares in the last quarter. Institutional investors own 69.20% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on CRSP shares. Barclays cut their price objective on shares of CRISPR Therapeutics from $67.00 to $59.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 6th. Truist Financial dropped their price target on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Royal Bank of Canada decreased their price objective on shares of CRISPR Therapeutics from $60.00 to $53.00 and set a “sector perform” rating for the company in a report on Friday, October 4th. Needham & Company LLC lowered their price objective on shares of CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a research report on Thursday, August 8th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $75.19.

Insider Activity

In other news, CEO Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the transaction, the chief executive officer now owns 226,540 shares in the company, valued at approximately $10,484,271.20. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CEO Samarth Kulkarni sold 4,293 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the sale, the chief executive officer now directly owns 226,540 shares in the company, valued at approximately $10,484,271.20. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, General Counsel James R. Kasinger sold 1,089 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the transaction, the general counsel now owns 62,597 shares in the company, valued at approximately $2,896,989.16. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Trading Up 9.4 %

NASDAQ CRSP opened at $50.76 on Friday. CRISPR Therapeutics AG has a 1 year low of $43.42 and a 1 year high of $91.10. The company has a market cap of $4.32 billion, a PE ratio of -15.72 and a beta of 1.68. The stock’s 50-day moving average price is $47.11 and its two-hundred day moving average price is $52.44.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, August 5th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06). The firm had revenue of $0.52 million for the quarter, compared to analyst estimates of $12.31 million. During the same quarter in the prior year, the company earned ($0.98) EPS. CRISPR Therapeutics’s revenue for the quarter was down 99.3% compared to the same quarter last year. Research analysts forecast that CRISPR Therapeutics AG will post -5.57 EPS for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.